Nitrofurantoin
Furadantin, Ivadantin, Macrobid, Macrodantin (nitrofurantoin) is a small molecule pharmaceutical. Nitrofurantoin was first approved as Furadantin on 1982-01-01. It is used to treat bacterial infections, escherichia coli infections, klebsiella infections, staphylococcal infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Furadantin, Macrodantin (generic drugs available since 1993-01-28, discontinued: Furalan, Ivadantin)
CombinationsMacrobid (generic drugs available since 1993-01-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitrofurantoin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FURADANTIN | Casper Pharma | N-009175 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Nitrofurantoin
+
Nitrofurantoin
+
macrocrystalline
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MACROBID | Almatica Pharma | N-020064 RX | 1991-12-24 | 1 products, RLD, RS |
Nitrofurantoin sodium
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
IVADANTIN | Procter And Gamble | N-012402 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Nitrofurantoin
+
macrocrystalline
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MACRODANTIN | Almatica Pharma | N-016620 RX | 1982-01-01 | 3 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
furadantin | New Drug Application | 2021-01-04 |
macrobid | New Drug Application | 2020-12-31 |
macrodantin | New Drug Application | 2020-06-01 |
nitrofurantoin macrocrystals | New Drug Application | 2023-05-16 |
nitrofurantoin monohydrate/ macrocrystalline | New Drug Application | 2023-06-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial infections | — | D001424 | A49 |
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
klebsiella infections | EFO_1001353 | D007710 | — |
staphylococcal infections | — | D013203 | A49.01 |
urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 2 | 4 | 12 | 4 | 23 |
Cystitis | D003556 | EFO_1000025 | N30 | — | 1 | — | 2 | — | 3 |
Nephrolithiasis | D053040 | N20.0 | — | — | — | 1 | 1 | 2 | |
Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 1 | 2 | |
Pulpitis | D011671 | EFO_1001139 | K04.0 | — | — | — | 2 | — | 2 |
Urinary bladder neoplasms | D001749 | C67 | — | — | — | 1 | — | 1 | |
Kidney calculi | D007669 | EFO_0004253 | N20.0 | — | — | — | 1 | — | 1 |
Stress urinary incontinence | D014550 | HP_0010992 | — | — | — | 1 | — | 1 | |
Postoperative pain | D010149 | G89.18 | — | — | — | 1 | — | 1 | |
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | N18 | — | — | 1 | — | — | 1 | |
Vesico-ureteral reflux | D014718 | EFO_0007536 | N13.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 3 | — | — | — | 1 | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sepsis | D018805 | A41.9 | — | — | — | — | 1 | 1 | |
Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | — | — | 1 | 1 |
Asymptomatic diseases | D058070 | — | — | — | — | 1 | 1 | ||
Hematuria | D006417 | HP_0000790 | R31 | — | — | — | — | 1 | 1 |
Pregnancy complications | D011248 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | NITROFURANTOIN |
INN | nitrofurantoin |
Description | Nitrofurantoin is an imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. It has a role as a hepatotoxic agent, an antiinfective agent and an antibacterial drug. It is an organonitrogen heterocyclic antibiotic, an organooxygen heterocyclic antibiotic, a nitrofuran antibiotic and an imidazolidine-2,4-dione. It is functionally related to a semicarbazide. |
Classification | Small molecule |
Drug class | antiepileptics (hydantoin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1 |
Identifiers
PDB | — |
CAS-ID | 67-20-9 |
RxCUI | 7454 |
ChEMBL ID | CHEMBL572 |
ChEBI ID | 71415 |
PubChem CID | 6604200 |
DrugBank | DB00698 |
UNII ID | 927AH8112L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Nitrofurantoin - RVL Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,275 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
606 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more